- Renalytix ( RNLX ) -28% on Q3 earnings release .
- Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease .
- Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq compliance .
- Hyperfine ( HYPR ) -20% as CEO Dave Scott steps down .
- Duck Creek Technologies ( DCT ) -17% on Q3 earnings release .
- Vinco Ventures ( BBIG ) -16% .
- Borr Drilling ( BORR ) -13% .
- Canopy Growth ( CGC ) -13% after announcing exchanges with holders of ~$198M of convertible notes .
- The9 ( NCTY ) -9% .
- RH ( RH ) -9% after trims fiscal 2022 outlook .
- Femasys ( FEMY ) -9% .
- Aethlon Medical ( AEMD ) -8% .
- Integrated Media Technology ( IMTE ) -8% .
- NeuroSense Therapeutics ( NRSN ) -8% after reports preliminary results from novel alzheimer's biomarker study .
- Can-Fite BioPharma ( CANF ) -8% .
- Wejo Group ( WEJO ) -7% .
- Verrica Pharmaceuticals ( VRCA ) -7% on pricing ~$25.2M of stock offering .
- MicroStrategy ( MSTR ) -8% as Bitcoin briefly falls below $19,000 as selling pressures continue .
- Universal Health Services ( UHS ) -7% after firm cuts FY2022 guidance over lower patient volumes .
- Agile Therapeutics ( AGRX ) -7% .
- ArcelorMittal ( MT ) -6% .
- Polestar Automotive Holding ( PSNY ) -6% .
- Benitec Biopharma ( BNTC ) -6% .
-
Lexicon Pharmaceuticals ( LXRX ) -1% eroding yesterday's gain on mid-stage study for diabetic neuropathy drug .
For further details see:
ArcelorMittal, Universal Health Services, RH among premarket losers' pack